Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri DSM17938 + bifidobacterium longum BB536
- Development stage
- Unknown
- Lead developer
- BioGaia
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This combination product pairs two clinically studied probiotic strains: *Lactobacillus reuteri* DSM 17938 and *Bifidobacterium longum* BB536. *L. reuteri* DSM 17938, a strain originally isolated from human breast milk and developed by BioGaia, is widely utilized for pediatric gastrointestinal disorders such as infant colic, regurgitation, and functional constipation. It works by modulating gut motility and reducing visceral pain. *Bifidobacterium longum* BB536, developed by Morinaga Milk Industry, is a stable, human-residential bifidobacterium that aids in restoring intestinal flora balance, improving bowel frequency, and enhancing immune function. The combination is frequently marketed for infant health and the management of dysbiosis.
- Brand names
- BioGaiaMorinaga
- Other names
- Limosilactobacillus reuteri DSM 17938Bifidobacterium longum BB536罗伊乳酸杆菌DSM17938 + 长双歧杆菌BB536
Beyond the preview
Go deeper on lactobacillus reuteri DSM17938 + bifidobacterium longum BB536.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri DSM17938 + bifidobacterium longum BB536.